{"id":"aadvac1-40-g","_chembl":{"chemblId":"CHEMBL3656159","moleculeType":"Small molecule","molecularWeight":"406.49"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Pathological tau protein","explanation":"AADvac1 is a synthetic peptide vaccine that targets misfolded tau protein. By inducing an active immune response, it aims to generate antibodies that can recognize and clear pathological tau aggregates, potentially slowing neurodegeneration in Alzheimer's disease and related tauopathies.","oneSentence":"Active immunotherapy that stimulates the immune system to produce antibodies against pathological tau protein aggregates in the brain."},"_scrapedAt":"2026-03-28T04:51:09.516Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123367,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"aducanumab","brand":"Aduhelm","company":"Biogen","rationale":"Monoclonal antibody targeting amyloid-beta in Alzheimer's disease"},{"name":"lecanemab","brand":"Leqembi","company":"Eisai/Biogen","rationale":"Anti-amyloid antibody for early Alzheimer's disease treatment"},{"name":"donanemab","brand":null,"company":"Eli Lilly","rationale":"Investigational anti-amyloid antibody for Alzheimer's disease"}],"description":"AADvac1 40 µg is an investigational active immunotherapy vaccine developed by Axon Neuroscience SE for the treatment of Alzheimer's disease. The vaccine is designed to stimulate the patient's immune system to produce antibodies against pathological tau protein, a key hallmark of Alzheimer's disease and other tauopathies.","indications":{"approved":[{"status":"investigational","condition":"Alzheimer's disease","patientPopulation":"Adult patients with mild to moderate Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT02579252","phase":"PHASE2","title":"24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease","status":"COMPLETED","sponsor":"Axon Neuroscience SE","startDate":"2016-03","conditions":"Alzheimer's Disease","enrollment":208},{"nctId":"NCT03174886","phase":"PHASE1","title":"A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia","status":"UNKNOWN","sponsor":"Axon Neuroscience SE","startDate":"2017-07-31","conditions":"Primary Progressive Nonfluent Aphasia","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AADvac1 40 µg","genericName":"AADvac1 40 µg","companyName":"Axon Neuroscience SE","companyId":"axon-neuroscience-se","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}